Application of a hemophilia mortality framework to the Emicizumab Global Safety Database.

CONCLUSIONS: No unique risk of death was associated with emicizumab prophylaxis in PwcHA. The data reveal that mortality in PwcHA receiving emicizumab was primarily associated with hemorrhage or non-HA-associated conditions, and was not reported by treaters to be related to emicizumab treatment. PMID: 33331041 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/33331041?dopt=Abstract

Source: Thrombosis and Haemostasis - December 19, 2020 Category: Hematology Authors: Peyvandi F, Mahlangu JN, Pipe SW, Hay CRM, Pierce GF, Kuebler P, Kruse-Jarres R, Shima M Tags: J Thromb Haemost Source Type: research